Literature DB >> 9643727

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

M C Ploy, C Grélaud, C Martin, L de Lumley, F Denis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9643727     DOI: 10.1016/s0140-6736(05)79166-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  73 in total

Review 1.  Antibiotic resistance: a current perspective.

Authors:  K F Barker
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

2.  Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital.

Authors:  A Marchese; G Balistreri; E Tonoli; E A Debbia; G C Schito
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Methicillin-Resistant Staphylococcus aureus Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

4.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France.

Authors:  X Bertrand; D Hocquet; M Thouverez; P Plésiat; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-12       Impact factor: 3.267

6.  Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

Authors:  Isabelle Verdier; Marie-Elisabeth Reverdy; Jerome Etienne; Gérard Lina; Michèle Bes; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

9.  Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mandy Wootton; T R Walsh; A P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.